Zobrazeno 1 - 10
of 95
pro vyhledávání: '"Meghan J, Mooradian"'
Autor:
Meghan J. Mooradian, Florian J. Fintelmann, Thomas J. LaSalle, Judit Simon, Alexander Graur, Alona Muzikansky, Mari Mino-Kenudson, Sophia Shalhout, Howard L. Kaufman, Russell W. Jenkins, Donald Lawrence, Aleigha Lawless, Tatyana Sharova, Raul N. Uppot, Jacy Fang, Emily M. Blaum, Anna L. K. Gonye, Irena Gushterova, Genevieve M. Boland, Christopher Azzoli, Nir Hacohen, Moshe Sade-Feldman, Ryan J. Sullivan
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-12 (2024)
Abstract Image-guided percutaneous cryoablation is an established minimally invasive oncologic treatment. We hypothesized that cryoablation may modify the immune microenvironment through direct modulation of the tumor, thereby generating an anti-tumo
Externí odkaz:
https://doaj.org/article/efad168e55d849beb3f3fc1c90d43fdb
Autor:
Laura C Cappelli, Bernice Kwong, Jarushka Naidoo, Jonathan Leventhal, Mario E Lacouture, Meghan J Mooradian, Douglas B Johnson, Justine Cohen, Aparna Hegde, Steven T Chen, Riley Fadden, Leyre Zubiri, Shawn Kwatra, Ryan J Sullivan, Kerry L Reynolds, Allison Betof Warner, Yevgeniy R Semenov, Nicole R LeBoeuf, Krista M Rubin, Anna K Dewan, Alina Markova, Allireza Alloo, Daniel Q Bach, Amina Bougrine, Leeann Burton, Mariana Castells, Lauren Guggina, Victor Huang, Benjamin Kaffenberger, Daniela Kroshinsky, Cecilia Larocca, Jon McDunn, Jennifer Choi, Vinod Nambudiri, Caroline A Nelson, Anisha B Patel, Julia Pimkina, Johnathan Rine, Maxwell Sauder, Sheila Shaigany, Afreen Shariff
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 12, Iss 4 (2024)
With an increasing number of patients eligible for immune checkpoint inhibitors, the incidence of immune-related adverse events (irAEs) is on the rise. Dermatologic immune-related adverse events (D-irAEs) are the most common and earliest to manifest,
Externí odkaz:
https://doaj.org/article/0f9ad47d419c4ad4b3131ec90c49be9f
Autor:
Omid Hamid, Diwakar Davar, Keisuke Shirai, Benjamin Izar, Charlotte E Ariyan, Michael K Wong, Jason J Luke, Janis M Taube, Anna C Pavlick, Meghan J Mooradian, Douglas B Johnson, Hussein A Tawbi, Tara C Mitchell, Ryan J Sullivan, April KS Salama, Krista M Rubin, Elizabeth I Buchbinder, Sarah A Weiss, Tina J Hieken, Geoffrey T Gibney, Rajan P Kulkarni, J Keith Tolley, Caressa Valdueza
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss 10 (2023)
Since the first approval for immune checkpoint inhibitors (ICIs) for the treatment of cutaneous melanoma more than a decade ago, immunotherapy has completely transformed the treatment landscape of this chemotherapy-resistant disease. Combination regi
Externí odkaz:
https://doaj.org/article/f4721e0504094c6083b6710589696855
Autor:
Bart Neyns, Lisa Zimmer, Caroline Robert, Celeste Lebbe, Olivier Michielin, Omid Hamid, Anne Zaremba, Oliver Klein, Ruth Plummer, Joanna Mangana, Paolo A Ascierto, Katharina C Kähler, Georgina V Long, Ryan Sullivan, Grant A McArthur, Michael Weichenthal, Egle Ramelyte, Meghan J Mooradian, Douglas B Johnson, Alexander Shoushtari, Christian U Blank, Judith M Versluis, Prachi Bhave, Claudia Trojanello, Lu Si, Inderjit Mehmi, Tasnia Ahmed, Alexander M Menzies, Adnan Khattak, Severine Roy, Matteo S Carlino, Paul C Lorigan, Clara Allayous, Rachel Roberts-Thomson, Florentia Dimitriou, Kathleen Batty, Thierry Lesimple, Serigne N Lo, Alexandre Wicky, Richard Heywood, Lena Tran, Anna Stansfeld, Julia K Schwarze, Andrea Maurichi, Hui-Ling Yeoh, Mario Santinami, Andrew M Haydon
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 7 (2022)
Background Acral melanoma is a rare melanoma subtype with poor prognosis. Importantly, these patients were not identified as a specific subgroup in the landmark melanoma trials involving ipilimumab and the anti-programmed cell death protein-1 (PD-1)
Externí odkaz:
https://doaj.org/article/0b1c2b670e1e4ec1b95b97b6b085c47b
Autor:
Jarushka Naidoo, Ryan Sullivan, Meghan J Mooradian, Leyre Zubiri, Vartan Pahalyants, Nicholas Theodosakis, Kerry L Reynolds, Yevgeniy R Semenov, Meghan E Sise, James Iheke, Pearl Ugwu-Dike, Jayhyun Seo, Kimberly Tang, Bruce C Tiu
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 6 (2022)
Externí odkaz:
https://doaj.org/article/e69c94c662834802beab88009e05effd
Autor:
Ayo S. Falade, Kerry L. Reynolds, Leyre Zubiri, Vikram Deshpande, Florian J. Fintelmann, Michael Dougan, Meghan J. Mooradian
Publikováno v:
Frontiers in Immunology, Vol 13 (2022)
Since the first approval of immune checkpoint inhibitors (ICIs) in 2011, these agents have rapidly become an integral treatment option across tumor types. However, with the increased adoption of ICIs, the incidence of immune-related adverse events (i
Externí odkaz:
https://doaj.org/article/d0ff8795a65a4f67827571a1d51912d6
Autor:
Andrew Haydon, Jessica C Hassel, Jeffrey A Sosman, Sunandana Chandra, Ryan Sullivan, Mario E Lacouture, Meghan J Mooradian, Alexander Menzies, Douglas B Johnson, Fei Ye, Prachi Bhave, Steven T Chen, Georgina Long, Briana Rose Halle, Farzana Y Zaman, Anna K Dewan, Rebecca Irlmeier, Paras Mehta, Nicholas R Kurtansky, Jacob S Choi, Tracey S Otto, Florentia Dimitriou, Veronica M Rotemberg
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 10 (2021)
Externí odkaz:
https://doaj.org/article/2404ddf91eb64426ad24a0c1ae12dd85
Autor:
Andrew L Mammen, Jarushka Naidoo, Divyanshu Dubey, Michael Dougan, Teilo H Schaller, Meghan J Mooradian, Douglas B Johnson, Jorg Dietrich, Leyre Zubiri, Tomas G Neilan, Bianca D Santomasso, Ryan J Sullivan, Kerry L Reynolds, Allison Betof Warner, Justine V Cohen, Nancy Wang, Jenny Linnoila, Jeffrey M Gelfand, Anthony A Amato, Stacey L Clardy, David A Reardon, William C Louv, Amanda C Guidon, Leeann B Burton, Bart K Chwalisz, James Hillis, Priscilla K Brastianos, Tracey A Cho, Christopher T Doughty, Jeffrey T Guptill, Vern C Juel, Robert Kadish, Noah Kolb, Nicole R LeBoeuf, Maria Martinez-Lage, Krista M Rubin, Karin Woodman
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 7 (2021)
Expanding the US Food and Drug Administration–approved indications for immune checkpoint inhibitors in patients with cancer has resulted in therapeutic success and immune-related adverse events (irAEs). Neurologic irAEs (irAE-Ns) have an incidence
Externí odkaz:
https://doaj.org/article/a2206707f599451b8603379684ad2015
Autor:
Michael S. Hughes, Hui Zheng, Leyre Zubiri, Gabriel E. Molina, Steven T. Chen, Meghan J. Mooradian, Ian M. Allen, Kerry L. Reynolds, Michael Dougan
Publikováno v:
Cancer Medicine, Vol 8, Iss 11, Pp 4986-4999 (2019)
Abstract Background Immune checkpoint inhibitors (CPIs) have revolutionized oncologic therapy but can lead to immune‐related adverse events (irAEs). Corticosteroids are first‐line treatment with escalation to biologic immunosuppression in refract
Externí odkaz:
https://doaj.org/article/dc34be1618d34608b433f3de2ca9f4c9
Predicting malignant potential of subsolid nodules: can radiomics preempt longitudinal follow up CT?
Autor:
Subba R. Digumarthy, Atul M. Padole, Shivam Rastogi, Melissa Price, Meghan J. Mooradian, Lecia V. Sequist, Mannudeep K. Kalra
Publikováno v:
Cancer Imaging, Vol 19, Iss 1, Pp 1-8 (2019)
Abstract Background To assess if radiomics can differentiate benign and malignant subsolid lung nodules (SSNs) on baseline or follow up chest CT examinations. If radiomics can differentiate between benign and malignant subsolid lung nodules, the clin
Externí odkaz:
https://doaj.org/article/f3ab845e3ddf4f8bb8ffb3b36c6f3a75